ReForm Biologics to present at the 13th annual PEGS Summit
CAMBRIDGE, Mass. – May 1, 2017 – ReForm Biologics, a pharmaceutical technology company developing an innovative platform to improve biologic formulations, announced today the issuance of U.S. patent 9,605,051 (the ‘051 patent) for one of its new excipient formulations.
An important application of the technology in this patent, entitled “Viscosity-Reducing Excipient Compounds for Protein Formulations,” covers the use of a new excipient that significantly reduces the viscosity of highly concentrated therapeutic antibody solutions. ReForm believes that viscosity reduction will allow for more effective formulation and preferable delivery of such antibody solutions to patients.
“Many antibody-based therapeutics need to be delivered intravenously due to their high dose requirements and viscosity in solution. Subcutaneous injection of a highly concentrated antibody solution is a preferred route for patients that require frequent and longer term treatment,” said John M. Sorvillo PhD, Chief Executive Officer. “The new excipient technology in the ‘051 patent enables high concentration formulations and will further enhance ReForm’s innovative platform for viscosity reduction of biotherapeutics. This new patent is a cornerstone of our proprietary technology platform to improve biologic formulations.”
ReForm Biologics also announced it will present a poster titled “A Fresh Perspective on Biologic Formulations” on May 3rd and May 4th at the 13th Annual PEGS Boston Summit at the Seaport World Trade Center in Boston, MA.
About ReForm Biologics
ReForm Biologics has developed a technology platform that transforms the formulation of biotherapeutics for the ultimate benefit of patients. Our patented FDA-friendly technology can extend product life-cycles, enable alternative dosing, and improve manufacturing efficiency for our biopharmaceutical partners. With multiple industry alliances to date, we offer formulation development collaborations and product-specific licenses for a broad spectrum of protein-based therapeutics.
We don’t make biologics — we make biologics better. www.reformbiologics.com
MacDougall Biomedical Communications